The purpose of the study is to estimate drug preference of stable schizophrenic patients who will be treated with olanzapine orodispersible tablets for 6 weeks then with olanzapine tablets for 6 weeks and vice-versa.

Inclusion Criteria:

• You are an outpatient diagnosed with stable schizophrenia.
• You are a male or female in the age of 18 to 65 years old.
• You are retrospectively judged by investigators, based on clinical interview and impression, to have been stable for at least 4 weeks.
• You must be able to take olanzapine orodispersible in a single daily dose.
• You are treated with conventional oral olanzapine tablet (as monotherapy) for at least 1 month.

Exclusion Criteria:

• You have used olanzapine in the past and are no longer using it because of a bad reaction.
• You have known Human immunodeficiency virus positive (HIV+) status.
• You have known uncorrected, narrow angle glaucoma.
• You have known Leukopenia, (abnormally low white blood cell count).
• You have a serious or uncontrolled illness (for example: liver disease, history of heart disease, or inadequately controlled diabetes.)
• You have Parkinson's disease.
• You are a female patient who is either pregnant or nursing
• You are taking medications that are not allowed in the study.

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.